Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Mathumai Kanapathipillai; Akiko Mammoto; Tadanori Mammoto; Joo H. Kang; Elisabeth Jiang; Kaustabh Ghosh; Netanel Korin; Ashley Gibbs; Robert Mannix; Donald E. Ingber

doi:10.1021/nl301206p

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Mathumai Kanapathipillai, Akiko Mammoto, Tadanori Mammoto, Joo H. Kang, Elisabeth Jiang, Kaustabh Ghosh, Netanel Korin, Ashley Gibbs, Robert Mannix, Donald E. Ingber

Research output: Contribution to journal › Article › peer-review

Abstract

A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

Original language	English
Pages (from-to)	3213-3217
Number of pages	5
Journal	Nano Letters
Volume	12
Issue number	6
DOIs	https://doi.org/10.1021/nl301206p
State	Published - 13 Jun 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
extracellular matrix
lysyl oxidase
mechanics
nanoparticle

All Science Journal Classification (ASJC) codes

Bioengineering
General Chemistry
General Materials Science
Condensed Matter Physics
Mechanical Engineering

Access to Document

10.1021/nl301206p

Cite this

@article{57798b95ae2948458ba48d841e54994f,

title = "Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix",

abstract = "A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.",

keywords = "Cancer, extracellular matrix, lysyl oxidase, mechanics, nanoparticle",

author = "Mathumai Kanapathipillai and Akiko Mammoto and Tadanori Mammoto and Kang, \{Joo H.\} and Elisabeth Jiang and Kaustabh Ghosh and Netanel Korin and Ashley Gibbs and Robert Mannix and Ingber, \{Donald E.\}",

year = "2012",

month = jun,

day = "13",

doi = "10.1021/nl301206p",

language = "الإنجليزيّة",

volume = "12",

pages = "3213--3217",

journal = "Nano Letters",

issn = "1530-6984",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

AU - Kanapathipillai, Mathumai

AU - Mammoto, Akiko

AU - Mammoto, Tadanori

AU - Kang, Joo H.

AU - Jiang, Elisabeth

AU - Ghosh, Kaustabh

AU - Korin, Netanel

AU - Gibbs, Ashley

AU - Mannix, Robert

AU - Ingber, Donald E.

PY - 2012/6/13

Y1 - 2012/6/13

N2 - A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

AB - A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

KW - Cancer

KW - extracellular matrix

KW - lysyl oxidase

KW - mechanics

KW - nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84862301989&partnerID=8YFLogxK

U2 - 10.1021/nl301206p

DO - 10.1021/nl301206p

M3 - مقالة

SN - 1530-6984

VL - 12

SP - 3213

EP - 3217

JO - Nano Letters

JF - Nano Letters

IS - 6

ER -

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this